Proud to Partner With:
Expertise Partner:
Antaros Medical is pioneering imaging methods, using MRI* and PET**, to both design and deliver clinical imaging studies. Applied with our extensive experience and expertise in drug development and disease biology, our tailored solutions have helped our customers to solve complex problems
to empower confident decision-making at every stage of clinical drug development, from small mechanistic studies to large scale studies. Disease areas: CV, renal and metabolic diseases and oncology.
Expertise Partner:
Truveta is a collective of 30 US health systems with a shared mission of Saving Lives with Data. Truveta accelerates therapy adoption with regulatory grade safety and effectiveness data replacing slow and expensive clinical trials and registries. Truveta and its health system members lead the Truveta Genome Project, creating the world’s largest and most diverse database of genotypic and phenotypic information to discover the science of humanity, accelerating discovery and improving patient care.
Expertise Partner:
Worldwide Clinical Trials is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare disease, and cardiometabolic and inflammatory disease. Its global footprint spans over 60 countries with more than 3,600 team members. For more information, visit
Expertise Partner:
Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH, dyslipidemia, inflammation, diabetic nephropathy, HFpEF and atherosclerosis. For >20 years, we have been evaluating the efficacy of our clients’ drugs using gold-standard experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners. Our expertise – your success.
Event Partner:
Gubra offers expert preclinical research services enabling pharmaceutical and biotech companies to advance their drug development pipeline. Our capabilities in preclinical studies include in vivo pharmacology, ex vivo assays, drug profiling, histology, stereology and whole brain and organ imaging. We employ a combination of unique techniques to profile drug
candidates in a wide array of clinically translatable research models.
Innovation Partner:
Clinical ink is the global life science company bringing data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with behavioral science, eDC/Direct Data Capture, eCOA, eConsent, telehealth, and digital biomarkers advancement (including the use of Continuous Glucose Monitoring for detection of hypoglycemia), support the next generation of clinical trials and ultimately, the clinical management of patients.
Innovation Partner:
CYTOO is a biotech company focused on muscle health and disease. CYTOO has pioneered MyoScreen™, an innovative in vitro screening platform that replicates the phenotypes, biomarkers and biochemical pathways affected in inherited and acquired muscle disorders. The platform, combined with our expertise in assay development and AI-driven image analysis, supports drug development at every stage of the pipeline, from disease modeling and primary screening to providing functional potency assays for clinical lot release. MyoScreen has successfully advanced several drug candidates into clinical trials during >60 industrial partnerships involving small molecules, peptides, antibodies, RNA and gene therapies. Our platform addresses a broad range of disease areas, including genetic neuromuscular disorders and muscle dysfunctions resulting from metabolic disturbances.
Hosting Partner: